Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
• Ongoing trials (RED-HF and TREAT) study the efficacy of raising haemoglobin
Barcelona, Spain, 30 August: Heart failure patients may benefit from treatment of anaemia similarly to those with chronic kidney disease (CKD) or cancer.
Anaemia is common to many diseases (chronic kidney disease, cancer, chronic heart failure) as well as a consequence of treatment for diseases such as cancer, specifically with chemotherapeutic agents. Anaemia may contribute to lethargy, reduced exercise tolerance and poor quality of life. Therefore, raising haemoglobin (Hb) in anaemic patients has long been thought to be a beneficial therapeutic goal. In contrast to CKD and cancer, attaining higher Hb targets does not appear to be associated with increased major events in early phase trials. On the other hand, the incremental benefit on exercise tolerance was also not large in these studies. Therefore, we are left with an equipoise situation in the treatment of the anaemia of heart failure, requiring a definitive outcome trial, which is currently occurring (RED-HF).
Erythropoietin is an endogenous hormone that raises Hb levels and various synthetic approaches have been developed to allow administration of this agent as a therapeutic. Improvements in patient symptom status and quality-of-life have consistently been observed in the literature with erythropoietin across a number of disease categories. However, a question has arisen as to whether there may be detrimental effects of raising Hb either too fast or to too high a level with these agents. In particular, studies in patients with anaemia of cancer and the treatment of cancer as well as with those in CKD have demonstrated that higher Hb targets are associated with adverse clinical outcomes including death and major cardiovascular events.
Prospective trials are needed to address this issue, by randomising patients to differing Hb targets and looking specifically at cardiovascular events. Such an ongoing large-scale study is TREAT, which is looking at erythropoietin in CKD patients with diabetes.
- Ends -
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2009. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved